替雷利珠单抗联合卡培他滨治疗晚期结直肠癌患者的临床效果OA
The Clinical Effect of Tislelizumab Combined with Capecitabine in the Treatment of Patients with Advanced Colorectal Cancer
目的:探讨替雷利珠单抗联合卡培他滨治疗方案在晚期结直肠癌患者中的临床应用价值.方法:纳入 2022 年 3 月—2023 年 7 月在呼和浩特市第一医院肿瘤内科收治的 76 例晚期结直肠癌患者,采用随机数字表法将其分为研究组和对照组,每组 38 例.研究组患者接受替雷利珠单抗联合卡培他滨治疗方案,对照组患者则采用卡培他滨单药治疗方案,以 21 d 为 1 个疗程,连续治疗 2 个疗程,记录并比较两组患者的临床疗效指标、肿瘤标志物水平、血管生成相关因子水平、不良反应发生情况及无进展生存期.结果:治疗后,研究组客观缓解率(objective response rate,ORR)和疾病控制率(disease control rate,DCR)高于对照组(P<0.05);在肿瘤标志物水平方面,研究组治疗后癌胚抗原(carcinoembryonic antigen,CEA)、糖类抗原 19-9(carbohydrate antigen 19-9,CA19-9)及糖类抗原 242(carbohydrate antigen 242,CA242)水平均低于对照组(P<0.05);在血管生成相关因子水平方面,研究组治疗后血管内皮生长因子(vascular endothelial growth factor,VEGF)、胰岛素样生长因子-1(insulin-like growth factor-1,IGF-1)及碱性成纤维细胞生长因子(basic fibroblast growth factor,bFGF)水平低于对照组(P<0.05);两组患者的不良反应发生率差异无统计学意义(P>0.05);生存分析显示,研究组患者的12个月无进展生存率高于对照组(P<0.05).结论:替雷利珠单抗联合卡培他滨的治疗方案能够显著提高晚期结直肠癌患者的临床效果,有效降低肿瘤标志物水平,抑制肿瘤血管生成,延长无进展生存期,且未增加不良反应发生率.
Objective:To explore the clinical application value of the Tislelizumab combined with Capecitabine treatment regimen in patients with advanced colorectal cancer.Method:A total of 76 patients with advanced colorectal cancer who were treated in the Department of Oncology of Huhhot First Hospital from March 2022 to July 2023 were included.They were divided into the study group and the control group by random number table method,with 38 cases in each group.Patients in the study group received the treatment regimen of Tislelizumab combined with Capecitabine,while patients in the control group were treated with Capecitabine monotherapy.The course of treatment was 21 days,and two consecutive courses of treatment were administered.The clinical efficacy indicators,levels of tumor marker,levels of angiogenesis-related factors,occurrence of adverse reactions,and progression-free survival of the two groups of patients were recorded and compared.Result:After treatment,the objective response rate(ORR)and disease control rate(DCR)of the study group were higher than those of the control group(P<0.05).In terms of tumor marker levels,after treatment,the levels of carcinoembryonic antigen(CEA),carbohydrate antigen 19-9(CA19-9)and carbohydrate antigen 242(CA242)in the study group were all lower than those in the control group(P<0.05).In terms of the levels of angiogenesis-related factors,after treatment,the levels of vascular endothelial growth factor(VEGF),insulin-like growth factor-1(IGF-1)and basic fibroblast growth factor(bFGF)in the study group were lower than those in the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Survival analysis showed that the 12-month progression-free survival rate of patients in the study group was higher than that in the control group(P<0.05).Conclusion:The treatment regimen of Tislelizumab combined with Capecitabine can significantly improve the clinical efficacy of patients with advanced colorectal cancer,effectively reduce the levels of tumor markers,inhibit tumor angiogenesis,prolong progression-free survival,and does not increase the incidence of adverse reactions.
王雪清;郝灵芳;梁润;杜晓帆
呼和浩特市第一医院肿瘤内科 内蒙古 呼和浩特 010031呼和浩特市中医蒙医医院血液肿瘤科 内蒙古 呼和浩特 010030呼和浩特市第一医院肿瘤内科 内蒙古 呼和浩特 010031呼和浩特市第一医院肿瘤内科 内蒙古 呼和浩特 010031
医药卫生
程序性细胞死亡蛋白-1抑制剂替雷利珠单抗卡培他滨晚期结直肠癌肿瘤标志物无进展生存期
Programmed cell death protein-1 inhibitorsTislelizumabCapecitabineAdvanced colorectal cancerTumor markersProgression-free survival
《中国医学创新》 2026 (22)
125-130,6
评论